Company news

Passage Bio, Inc. news in 2024

Passage Bio, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

November 12, 2024

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

September 15, 2024

Passage Bio Welcomes Tom Kassberg to Board of Directors

September 9, 2024

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

August 7, 2024

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

July 31, 2024

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

July 15, 2024

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

May 20, 2024

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

May 13, 2024

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

March 3, 2024

Decks in 2024